GSK

GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma

Will Pfizer’s Lyme Disease Gamble Pay Off or Set the Space Back?

First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More

FTSE 100 Holds Near‑Flat as UK Investors Await US‑Iran Peace Talks

GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run

GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102

10 Best Low-Risk Investments in May 2026

Daraxonrasib (RMC-6236): The 2025 Molecule of the Year

Lilly Gets Back in Infectious Disease, via Three M&A Deals

Be Creative, Not A Cowboy: Attorneys Talk Litigation Collaboration Pitfalls

GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial

Pharma and Biotech Layoffs 2026 Watch

GSK Returns Rights to Wave's RNA Editing Program for AATD

GSK’s Hepatitis B Drug Shows Functional Cure in 1 in 5 Patients

‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies

Hepatitis Vaccine Uptake Declining, Liver Disease Could Increase

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability

Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies

Linvoseltamab Data ‘Encouraging’ in Relapsed AL Amyloidosis

JPM26: Filling C-Suites, Union Square—And Elevators—With Pink

Gepotidacin

Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B

Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for Global Biopharma and Healthcare Sectors

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Innoviva, Inc. (INVA) Draws Bullish View From Cantor on Recurring Royalty Strength

The New Mixed-Use Must: Data Centres

Sunshine Biopharma Inc (SBFM) Q4 2025 Earnings Call Transcript

Altimmune Reports the P-IIb (IMPACT) Trial Data on Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

STAT+: GSK Picks up Pulmonary Hypertension Drug with 35Pharma Acquisition

GSK’s RSV Vaccine Approved in Europe

FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug

9 Companies Hiring Now in Pennsylvania

FDA Clears GSK’s Gepotidacin, First New Oral UTI Antibiotic in 30 Years

GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+

Our Aging Population Is Forcing a Rethink of How We Design & Package Medicines

FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis

GSK Makes $2.2B Deal for RAPT and Its Food Allergy Candidate

Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals

GSK, Noetik Sign Cancer Deal on AI Virtual Cell Models

Maryland’s Biopharma Cluster Takes on Coastal Hubs

China Clears Mepolizumab for COPD

DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer

GSK’s Bepirovirsen Achieves Functional Cure in 19% of Hepatitis B Patients in Phase III Trials

Halozyme Q1 Revenue Jumps 42% to $377 M on ENHANZE Therapy Surge

'Skinny' Generic Vascepa Label Case Reaches US Supreme Court

Tahoe, Arc Institute, and Biohub Join Forces on Massive Virtual Cell Dataset

The New Gold Rush in Brain Science

The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine

Lactalis Canada Appoints Sales and Marketing Leadership for Cheese and Tablespreads

Samsung Biologics Acquires GSK's Vaccine R&D Assets for $280M

GSK to Acquire RAPT for $2.2B

GSK to Acquire 35Pharma for Under $1B

Wave Life Sciences Reacquires Global Rights to RNA Editing Drug WVE-006 From GSK

GSK Acquires RAPT Therapeutics for $2.2B